Objective To investigate the therapeutic effects of combined magnetic and electrical stimulation with an"intelligent exercise prescription"and novel matrix radiofrequency therapy in patients with pelvic organ prolapse(POP).Methods A total of 158 patients with POP who received treatment at the Gynecological Pelvic Floor Rehabilitation Center of the Eighth Affiliated Hospital of Southern Medical University between October 2022 and July 2025 were retrospectively enrolled and divided into an observation group(n=64)and a control group(n=94)based on their treatment plans.The control group underwent magnetic and electrical stimulation combined with an"intelligent exercise prescription"regimen.Specifically,patients received 10 sessions of electrical stimulation,5 sessions of magnetic stimulation,and performed 15～20 minutes of daily home exercise training guided by the"intelligent exercise prescription."The observation group received,in addition to the aforementioned treatments,four sessions of novel matrix radiofrequency therapy.Changes in the muscle strength grades of type Ⅰ and type Ⅱ pelvic floor muscles,Glazer surface electromyography(EMG)values,and POP-Q staging were compared between the two groups before and after treatment.Results After treatment,both groups demonstrated significant improvements in type Ⅰ and type Ⅱ muscle fiber strength compared to baseline(all P<0.05),with the observation group showing greater improvement in type Ⅰ muscle fiber strength than the control group(P<0.05).The muscle potential values of the observation group during rapid contraction,tense contraction,and endurance contraction stages were markedly increased compared to pre-treatment levels.Moreover,the muscle potential values during the pre-resting stage were significantly reduced after treatment(P<0.05).In the observation group,POP-Q grades of the anterior vaginal wall,uterus,and posterior vaginal wall were all significantly lower post-treatment than pre-treatment(all P<0.05).However,no statistically significant differences were observed between the observation group and the control group in these parameters(P>0.05).Both groups exhibited relatively high compliance rates(both≥75.0%),with no significant difference between them(P>0.05).The treatment cost for the observation group was significantly higher than that for the control group(P<0.05).Conclusions The combination of magneto-electrical stimulation,an"intelligent exercise prescription,"and novel matrix radiofrequency therapy can significantly improve pelvic floor muscle strength and muscle potential values in the short term,compared to pre-treatment levels.This integrated approach also effectively alleviates the prolapse of the anterior vaginal wall,uterus,and posterior vaginal wall.Furthermore,the combination of magnetic and electrical stimulation,"intelligent exercise prescription,"and matrix radiofrequency therapy demonstrates superior efficacy in enhancing type Ⅰ pelvic floor muscle fiber strength when compared to the combination of magnetic and electrical stimulation with"intelligent exercise prescription"alone.However,this treatment protocol entails a relatively high economic burden,and its clinical application should be carefully evaluated in consideration of patients'functional needs and financial conditions.

Objective To investigate the therapeutic effects of combined magnetic and electrical stimulation with an"intelligent exercise prescription"and novel matrix radiofrequency therapy in patients with pelvic organ prolapse(POP).Methods A total of 158 patients with POP who received treatment at the Gynecological Pelvic Floor Rehabilitation Center of the Eighth Affiliated Hospital of Southern Medical University between October 2022 and July 2025 were retrospectively enrolled and divided into an observation group(n=64)and a control group(n=94)based on their treatment plans.The control group underwent magnetic and electrical stimulation combined with an"intelligent exercise prescription"regimen.Specifically,patients received 10 sessions of electrical stimulation,5 sessions of magnetic stimulation,and performed 15～20 minutes of daily home exercise training guided by the"intelligent exercise prescription."The observation group received,in addition to the aforementioned treatments,four sessions of novel matrix radiofrequency therapy.Changes in the muscle strength grades of type Ⅰ and type Ⅱ pelvic floor muscles,Glazer surface electromyography(EMG)values,and POP-Q staging were compared between the two groups before and after treatment.Results After treatment,both groups demonstrated significant improvements in type Ⅰ and type Ⅱ muscle fiber strength compared to baseline(all P<0.05),with the observation group showing greater improvement in type Ⅰ muscle fiber strength than the control group(P<0.05).The muscle potential values of the observation group during rapid contraction,tense contraction,and endurance contraction stages were markedly increased compared to pre-treatment levels.Moreover,the muscle potential values during the pre-resting stage were significantly reduced after treatment(P<0.05).In the observation group,POP-Q grades of the anterior vaginal wall,uterus,and posterior vaginal wall were all significantly lower post-treatment than pre-treatment(all P<0.05).However,no statistically significant differences were observed between the observation group and the control group in these parameters(P>0.05).Both groups exhibited relatively high compliance rates(both≥75.0%),with no significant difference between them(P>0.05).The treatment cost for the observation group was significantly higher than that for the control group(P<0.05).Conclusions The combination of magneto-electrical stimulation,an"intelligent exercise prescription,"and novel matrix radiofrequency therapy can significantly improve pelvic floor muscle strength and muscle potential values in the short term,compared to pre-treatment levels.This integrated approach also effectively alleviates the prolapse of the anterior vaginal wall,uterus,and posterior vaginal wall.Furthermore,the combination of magnetic and electrical stimulation,"intelligent exercise prescription,"and matrix radiofrequency therapy demonstrates superior efficacy in enhancing type Ⅰ pelvic floor muscle fiber strength when compared to the combination of magnetic and electrical stimulation with"intelligent exercise prescription"alone.However,this treatment protocol entails a relatively high economic burden,and its clinical application should be carefully evaluated in consideration of patients'functional needs and financial conditions.

[Objective]Our study seeks to investigate the connection between systemic immune inflammatory index and renal function,as well as to assess its predictive capacity for the deterioration of renal function in chronic kidney disease patients with non-dialysis.[Methods]Adult non-dialyzing patients diagnosed with CKD were included.The computation of SII was calculated as the product of the peripheral blood neutrophil count(×10?/L)and platelet count(×10?/L),divided by the lymphocyte count(×10?/L).The logistic and Cox regression models were employed to scrutinize the linkage between SII levels and CKD.[Results]Out of the cohort,a significant portion of patients,numbering 244,which constitutes 17.2％,experienced progression of CKD.A notable upsurge in SII corresponded with an increased prevalence of advanced CKD and its progression,with significant difference.This trend was mirrored by a decline in the estimated glomerular filtration rate and hemoglobin levels,while serum creatinine,C-reactive protein,and lipoprotein(a)levels were on the rise.After adjusting for multiple variables,the natural logarithm of SII exhibited an independent association with advanced CKD[OR=1.85 95％CI(1.46,2.35),P<0.01].Furthermore,Cox proportional hazards model analysis revealed that SII acted as an independent predictor for CKD progression[adjusted HR=1.35,95％CI(1.09,1.67),P<0.01].Subgroup analysis indicated a significant interaction among SII,gender,and hypertension concerning CKD progression.[Conclusion]Our findings underscore the robust relationship between SII and renal function,positioning SII as a potential forecaster for the progression of CKD.

Objective:To evaluate the cardiovascular safety of febuxostat and allopurinol in patients with gout/hyperuricemia, and to explore the difference in cardiovascular safety between Asian and non-Asian patients.Methods:Randomized controlled trials (RCTs) and cohort studies of comparision of cardiovascular safety between febuxostat (the trial group) and allopurinol (the control group) in the treatment of gout/hyperuricemia were collected by searching related databases at home and abroad (up to October, 2021). The outcome indicators were the incidences of acute decompensated heart failure (ADHF), stroke, acute coronary syndrome (ACS), coronary revascularization, death from cardiovascular causes, and all-cause death. The Cochrane collaboration risk of bias risk tool and Newcastle Ottawa Scale were used to evaluate the quality of the RCTs and the cohort studies, respectively. RevMan 5.4 software was used for meta-analysis, and the effect sizes were relative risk ( RR) and its 95% confidence interval ( CI). Results:A total of 9 RCTs and 7 cohort studies were enrolled in the analysis and 385 700 patients were involved, including 123 565 in the trial group and 262 135 in the control group. The results of quality evaluation showed that there were 4 and 5 RCTs with low and uncertain bias risk in 9 RCTs, respectively; among the 7 cohort studies, 2 and 5 were of high and medium quality, respectively. The result of meta-analysis of RCTs showed that the incidence of ADHF in the trial group was significantly lower than that in the control group [1.37% (77/5 620) vs. 2.21% (102/4 607), RR=0.74, 95 %CI: 0.55-0.99, P=0.04]. The result of meta-analysis of cohort studies showed that the incidence of stroke in Asian patients in the trial group was lower than that in the control group [0.87% (519/59 559) vs. 0.90% (810/89 836), RR=0.94, 95 %CI: 0.75-1.17, P=0.58]; the incidence of stroke in non-Asian patients in the trial group was lower than that in the control group, and the difference was statistically significant [1.49% (377/25 306) vs. 1.70% (1 305/76 864), RR=0.88, 95 %CI: 0.78-0.98, P=0.02]; the incidence of cardiovascular death in Asian patients in the trial group was higher than that in the control group [0.96% (473/49 373) vs. 0.68% (335/49 368), RR=1.41, 95 %CI: 1.23-1.62, P<0.01]. Conclusions:The risk of ADHF caused by febuxostat is lower than that caused by allopurinol; the risk of stroke caused by febuxostat is lower than that caused by allopurinol in non-Asian patients; the risk of cardiovascular death caused by febuxostat is higher than that caused by allopurinol in Asian patients.

Objective:To evaluate the cardiovascular safety of febuxostat and allopurinol in patients with gout/hyperuricemia, and to explore the difference in cardiovascular safety between Asian and non-Asian patients.Methods:Randomized controlled trials (RCTs) and cohort studies of comparision of cardiovascular safety between febuxostat (the trial group) and allopurinol (the control group) in the treatment of gout/hyperuricemia were collected by searching related databases at home and abroad (up to October, 2021). The outcome indicators were the incidences of acute decompensated heart failure (ADHF), stroke, acute coronary syndrome (ACS), coronary revascularization, death from cardiovascular causes, and all-cause death. The Cochrane collaboration risk of bias risk tool and Newcastle Ottawa Scale were used to evaluate the quality of the RCTs and the cohort studies, respectively. RevMan 5.4 software was used for meta-analysis, and the effect sizes were relative risk ( RR) and its 95% confidence interval ( CI). Results:A total of 9 RCTs and 7 cohort studies were enrolled in the analysis and 385 700 patients were involved, including 123 565 in the trial group and 262 135 in the control group. The results of quality evaluation showed that there were 4 and 5 RCTs with low and uncertain bias risk in 9 RCTs, respectively; among the 7 cohort studies, 2 and 5 were of high and medium quality, respectively. The result of meta-analysis of RCTs showed that the incidence of ADHF in the trial group was significantly lower than that in the control group [1.37% (77/5 620) vs. 2.21% (102/4 607), RR=0.74, 95 %CI: 0.55-0.99, P=0.04]. The result of meta-analysis of cohort studies showed that the incidence of stroke in Asian patients in the trial group was lower than that in the control group [0.87% (519/59 559) vs. 0.90% (810/89 836), RR=0.94, 95 %CI: 0.75-1.17, P=0.58]; the incidence of stroke in non-Asian patients in the trial group was lower than that in the control group, and the difference was statistically significant [1.49% (377/25 306) vs. 1.70% (1 305/76 864), RR=0.88, 95 %CI: 0.78-0.98, P=0.02]; the incidence of cardiovascular death in Asian patients in the trial group was higher than that in the control group [0.96% (473/49 373) vs. 0.68% (335/49 368), RR=1.41, 95 %CI: 1.23-1.62, P<0.01]. Conclusions:The risk of ADHF caused by febuxostat is lower than that caused by allopurinol; the risk of stroke caused by febuxostat is lower than that caused by allopurinol in non-Asian patients; the risk of cardiovascular death caused by febuxostat is higher than that caused by allopurinol in Asian patients.

BACKGROUND:Posterior stabilized femoral knee prosthesis needs additional condyle osteotomy to accommodate the tibial post and femur fossa structures. Intercondylar fossa on both sides connected at the femoral body with concentrated stress is a place easily affecting fractures. Differences in bone mass between different models of different brands did not have specific data, which was not convenient to select prosthesis for clinicians.
OBJECTIVE: To compare the difference of intercondylar osteotomy data among clinical commonly used posterior stabilized knee prostheses (six imported and domestic brands), and to provide basis for the selection and application of the prostheses.
METHODS:The current commonly used posterior stabilized knee prostheses (six imported and domestic brands) were used, including Zimmer NexGen LPS, Stryker Scrorpio NRG Knee-Flexed, Depuy PFC Sigma, Smith & nephew Genesis-2 PS, United-U1 and Wego GKPS. According to the osteotomy template, the osteotomy-surfaces consisting of femoral condyle starting section and cross section, distal section of femoral condyle, and back-oblique section were identified. The corresponding femoral prosthesis diameter lines included condylar ambilateral and anteroposterior diameters, width and depth of femoral intercondylar fossa. The above data were compared and measured.
RESULTS AND CONCLUSION:The six kinds of knee femoral prostheses were different in ratio of ambilateral diameter and anteroposterior diameter, bone resection of intercondylar fossa, and geometry. Imported prostheses carry shorter diameters in femoral starting and cross sections, so it can catch more posterior condylar osteotomy. With increasing prosthesis sizes, the ratio of bone loss causing by width of intercondylar osteotomy is decreased among six brands. In al sizes, Stryker Scrorpio NRG Knee-Flexed catches shorter width of intercondylar osteotomy. Knee prosthesis osteotomy among six brands is different. The result of this study is not sufficient to evaluate the pros and cons between different prostheses, but as reserving bone is concerned, the design of less intercondylar osteoomy catches more advantages.